Compare CAE & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | ALKS |
|---|---|---|
| Founded | 1947 | 1987 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.7B |
| IPO Year | 2002 | 2012 |
| Metric | CAE | ALKS |
|---|---|---|
| Price | $25.18 | $52.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $33.33 | ★ $43.43 |
| AVG Volume (30 Days) | 522.2K | ★ 1.8M |
| Earning Date | 05-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $4.97 | $24.26 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | $35.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.76 | $25.17 |
| 52 Week High | $34.24 | $55.67 |
| Indicator | CAE | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 59.36 |
| Support Level | $24.77 | $50.49 |
| Resistance Level | $26.18 | $55.67 |
| Average True Range (ATR) | 0.62 | 1.58 |
| MACD | -0.03 | -0.50 |
| Stochastic Oscillator | 41.50 | 40.40 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: i) Civil Aviation: Provides comprehensive training solutions for flight, cabin, maintenance, ground personnel and air traffic controllers in commercial, business and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training and crew sourcing services, as well as airline operations digital solutions; and ii) Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.